Changes at the top of commercial units for Gilead and BMS

Christopher Boerner was promoted to lead commercial at BMS, and Laura Hamill joined Gilead from Amgen to head up its commercial operations.

After failure of generic fish oil trial, some caution against read-across to Vascepa study

Amarin's Vascepa trial is set to read out results by the end of September.

Q&A: Matt McNally on the road ahead for Outcome Health and the state of the POC union

Q&A: Matt McNally on the road ahead for Outcome Health and the state of the POC union

Matt McNally, CEO of Outcome Health, shares his thoughts on post-controversy Outcome Health and the overall state of the point-of-care union.

Media buyers form group to advance standards in POC

Media buyers form group to advance standards in POC

Among the group's members are media agencies that had pulled healthcare ad spend from the POC channel in the wake of a scandal 10 months ago.

GSW's creative council looks to 'protect ideas, nurture them,' and solve human problems

GSW's creative council looks to 'protect ideas, nurture them,' and solve human problems

GSW's creative council met for an honest discussion about the agency-client relationship, the tension between data and emotional connection, industry trends, and creativity in the face of regulation.

Five things for pharma marketers to know: Wednesday, August 29, 2018

Five things for pharma marketers to know: Wednesday, August 29, 2018

Gilead appoints new commercial lead; U.K. bans online ad for contraception app; Pfizer petitions the FDA to clarify biosimilar communications.

'If WPP's next CEO isn't Mark Read, it's got to be a spectacular choice,' analysts say

'If WPP's next CEO isn't Mark Read, it's got to be a spectacular choice,' analysts say

Some of the advertising industry's top analysts say Mark Read looks the best choice to be WPP's chief executive and the board would need to find a "spectacular" alternative.

Five things for pharma marketers to know: Tuesday, August 28, 2018

Five things for pharma marketers to know: Tuesday, August 28, 2018

Gilead's CAR-T cell therapy ruled too expensive in the U.K.; Experts mixed on impact of drug price hike freezes; Women turn to wearables for fertility tracking

Experts split on impact of drug price hike freezes

Experts split on impact of drug price hike freezes

Some of the world's most powerful pharmaceutical companies backed down on planned price increases following a new transparency law in California and social media hectoring from President Donald Trump.

Five things for pharma marketers to know: Monday, August 27, 2018

Five things for pharma marketers to know: Monday, August 27, 2018

Pfizer's drug tafamidis reduces risk of death; Lilly Diabetes pulls its sponsorship of Daly's car; FDA investigates electronic cigarette maker Juul.

The highs and lows of cannabis branding

The highs and lows of cannabis branding

Chase Design Group's John Tanner shares what he thinks brands can do to spice things up when it comes to marketing around marijuana.

Got name? A peek into the sometimes bizarre land of pharma brand-naming

Got name? A peek into the sometimes bizarre land of pharma brand-naming

As more medications are approved, pharma companies are being pushed farther afield into a land of bizarre — but hopefully still memorable and vaguely meaningful — drug names.

Five things for pharma marketers to know: Friday, August 24, 2018

Five things for pharma marketers to know: Friday, August 24, 2018

White House proposes rule for drug prices in DTC ads; FDA to study impact of side-effects warnings in drug ads; FDA approves Shire's potential blockbuster HAE treatment.

Behind the Exact Sciences/Pfizer Cologuard co-promotion deal

Behind the Exact Sciences/Pfizer Cologuard co-promotion deal

The companies plan to make the most of favorable market access conditions for the at-home colon cancer screening test.

Pfizer lawsuit could clear path for biosimilars

Pfizer lawsuit could clear path for biosimilars

Biosimilars have only been in the market for three years, but they have struggled to compete with their branded equivalents.